ClinicalTrials.gg
Active, not recruitingNCT04852198Roux-en-WHY?Updated Oct 29, 2026

Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial

An interventional study of OAGB and RYGB in Bariatric Surgery Candidate, Obesity and Obesity, Morbid, sponsored by Flevoziekenhuis. Active, not recruiting at 2 sites in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Flevoziekenhuis · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Obesity, Morbid with a site in Netherlands — 2 open to participants now, 7 under way, none of them phase 3. Obesity, Morbid · Netherlands.

Planned enrollment
3rd of 24
298 · median 90
Started
2021
with 2 others
No phase
14 of 31
1 open now
Registered
23rd of 31
by date
Lead sponsor
1 of 31
Flevoziekenhuis

Among the 31 studies in Obesity, Morbid with a site in Netherlands, this one is the 3rd largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 with no phase, and was the 23rd registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

2 of the 31 studies in Obesity, Morbid with a site in Netherlands are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Obesity, Morbid with a site in Netherlands, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficiency of OAGB compared to RYGB

Read the detailed description

Rationale: to compare two different types of gastric bypass operations on surgical outcome.

Objective: to compare two established procedures in order to find the optimal procedure in terms of weight loss and metabolic control that is associated with the fewest side-effects and complications, and decreased invasiveness.

Study design: A multicentre, open label, non-inferiority randomized controlled trial Study population: Patients are eligible for inclusion if their body-mass index (BMI) was 40 kg/m2 or higher, or 35 kg/m2 or higher with the presence of at least one comorbidity (type 2 diabetes, high blood pressure, obstructive sleep apnoea, dyslipidaemia, osteoarthritis of the hip or knee) and a positive evaluation by our bariatric multidisciplinary team (BMDT) and are aged 18-65.

Intervention: Group 1: One Anastomosis Gastric Bypass with 150cm biliopancreatic limb. Group 2: Roux-en-Y gastric bypass with biliopancreatic limb of 150cm and 75cm alimentary limb.

Main study parameters/endpoints:

Primary endpoint:

% Excess BMI loss at two years

Secondary endpoints:

Metabolic status Nutritional status Comorbidity remission QOL Complications or serious adverse events (SAE's)

03

Conditions studied

  • Bariatric Surgery Candidate
  • Obesity
  • Obesity, Morbid

Browse trials for

04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 298 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Flevoziekenhuis is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • body-mass index () of 40 kg/m2 or higher, or 35 kg/m2 or higher with the presence of at least one comorbidity (type 2 diabetes, high blood pressure, obstructive sleep apnoea, dyslipidaemia, osteoarthritis of the hip or knee)
  • a positive evaluation by our BMDT

Exclusion criteria

Exclusion Criteria:

  • Presence of H. Pylori, resistant to eradication therapy
  • chronic diarrhoea
  • history of previous bariatric or extensive abdominal surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
298 participants (estimated)

Study arms

  • Active comparator
    OAGB

    149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm

    Procedure: OAGB

  • Active comparator
    RYGB

    149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm

    Procedure: RYGB

Interventions

  • ProcedureOAGB

    Simplified gastric bypass procedure

    Also known as: Mini gastric bypass, Omega loop gastric bypass

  • ProcedureRYGB

    Roux-en-Y gastric bypass. Standard procedure in the Netherlands

07

What researchers measure

Primary outcomes

  1. Percentage excess BMI loss at 2 years (%EBMIL)

    Percentage excess BMI loss after 2 years of follow-up

    Time frame: 2 years

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for May 2028, 76 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 76 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2027 → May 2028 and completion Nov 2029 → May 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Apr 21, 2021
StartActual
Dec 13, 2021
Primary completionEst.
May 1, 2028was Jun 2027
CompletionEst.
May 1, 2031was Nov 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Flevoziekenhuis · Almere Stad, Netherlands
Show 1 removed
  • Flevoziekenhuis · Almere, Netherlands
Oct 29, 2026
Primary completion
Jun 13, 2027→May 1, 2028
Oct 29, 2026
Study completion
Nov 1, 2029→May 1, 2031
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Flevoziekenhuis · Almere Stad, Netherlands
    Show 1 removed
    • Flevoziekenhuis · Almere, Netherlands
    Primary completion Jun 13, 2027→May 1, 2028
    Study completion Nov 1, 2029→May 1, 2031
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04852198
Lead sponsor
Flevoziekenhuis
Responsible party
Sponsor
First posted
Apr 21, 2021
Start date
Dec 13, 2021
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Oct 29, 2026

Study contacts

Stef JM Smeets, MD PhD
principal investigator · Flevoziekenhuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion